Sera Prognostics, Inc.
$2.29
▼
-2.9%
2026-04-21 09:22:00
www.sera.com
NGM: SERA
Explore Sera Prognostics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$90.03 M
Current Price
$2.29
52W High / Low
$4.09 / $1.37
Stock P/E
—
Book Value
$1.94
Dividend Yield
—
ROCE
-46.95%
ROE
-51.83%
Face Value
—
EPS
$-0.67
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
71
Beta
1.06
Debt / Equity
3.1
Current Ratio
1.69
Quick Ratio
1.69
Forward P/E
-2.94
Price / Sales
952.02
Enterprise Value
$40.25 M
EV / EBITDA
-1.13
EV / Revenue
496.93
Rating
None
Target Price
$5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Baird Medical Investment Holdings Limited | $1.79 | 55.75 | $64.64 M | — | 35.34% | -8.03% | $7.26 / $0.76 | $1.34 |
| 2. | RxSight, Inc. | $7.44 | — | $314.04 M | — | -16.88% | -13.98% | $16.74 / $5.9 | $6.68 |
| 3. | 20/20 Biolabs, Inc. | $1.71 | — | — | — | -253.94% | -5.03% | $50 / $1.51 | $0.01 |
| 4. | Owlet, Inc. | $5.82 | — | $163.61 M | — | -19.96% | -8.02% | $16.94 / $3.08 | $0.71 |
| 5. | Avanos Medical, Inc. | $24.64 | — | $1.15 B | — | 1.7% | -9.07% | $24.72 / $9.3 | $16.75 |
| 6. | Viemed Healthcare, Inc. | $9.66 | 24.97 | $372.9 M | — | 13.1% | 11.11% | $10.06 / $5.93 | $3.72 |
| 7. | Neuronetics, Inc. | $1.58 | — | $109.46 M | — | -28.31% | -1.35% | $4.85 / $0.8 | $0.32 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0.01 M | 0.02 M | 0.02 M | 0.04 M | 0.02 M |
| Operating Profit | -8.95 M | -8.98 M | -9.32 M | -9.25 M | -9.42 M |
| Net Profit | -7.88 M | -7.81 M | -8.05 M | -8.19 M | -8.58 M |
| EPS in Rs | -0.21 | -0.2 | -0.21 | -0.21 | -0.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.08 M | 0.08 M | 0.31 M | 0.27 M |
| Operating Profit | -36.5 M | -36.63 M | -39.82 M | -45.65 M |
| Net Profit | -31.93 M | -32.9 M | -36.24 M | -44.19 M |
| EPS in Rs | -0.84 | -0.86 | -0.95 | -1.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 101.93 M | 72.58 M | 95.44 M | 116.33 M |
| Total Liabilities | 26.52 M | 24.77 M | 25.28 M | 17.39 M |
| Equity | 75.41 M | 47.8 M | 70.16 M | 98.94 M |
| Current Assets | 40.77 M | 47.6 M | 61.34 M | 90.12 M |
| Current Liabilities | 24.19 M | 24.77 M | 24.44 M | 15.54 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -25.62 M | -14.19 M | -27.19 M | -34.61 M |
| Investing CF | -28.5 M | 11.74 M | 0.44 M | 5.55 M |
| Financing CF | 54.03 M | 2.61 M | 0.75 M | 0.01 M |
| Free CF | -26.35 M | -15.29 M | -27.32 M | -35.4 M |
| Capex | -0.73 M | -1.1 M | -0.13 M | -0.79 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -74.84% | 14.18% | — | — |
| Earnings Growth % | 9.23% | 17.98% | — | — |
| Profit Margin % | -42724.68% | -11843.79% | -16487.31% | — |
| Operating Margin % | -47577.92% | -13013.4% | -17034.33% | — |
| Gross Margin % | -6.49% | 31.37% | 27.99% | — |
| EBITDA Margin % | -41606.49% | -11531.7% | -16182.46% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.